Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitors”

2,466 pharma patents match "inhibitors" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,466
Index total 30,257
Page 6 / 103

Quick answer

This filtered view shows 2,466 pharmaceutical patents matching "inhibitors" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,466 results for “inhibitors” · 30,257 patents in full index Clear search

  1. US 12145944

    Imidazopyrimidines as EED inhibitors and the use thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  2. US 12145925

    Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer

    The Regents of the University of California · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  3. US 12138263

    Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof

    Relay Therapeutics, Inc. · Granted Nov 12, 2024 · Expires Nov 7, 2044

    granted
  4. US 12129262

    CDK inhibitors and their use as pharmaceuticals

    Prelude Therapeutics, Incorporated · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  5. US 12128015

    APE/REF1 inhibitors for the treatment of cancer

    The Regents of the University of California · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  6. US 12129263

    Kinase inhibitors and uses thereof

    DENALI THERAPEUTICS INC. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  7. US 12128048

    Combination therapies using PRMT5 inhibitors for the treatment of cancer

    Mirati Therapeutics, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  8. US 12121524

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  9. US 12123001

    Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  10. US 12121540

    CBL inhibitors and compositions for use in adoptive cell therapy

    NURIX THERAPEUTICS, INC. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  11. US 12116346

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  12. US 12115156

    Compositions of CXCR4 inhibitors and methods of preparation and use

    X4 Pharmaceuticals, Inc. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  13. US 12116343

    Inhibitors of APOL1 and methods of using same

    Vertex Pharmaceuticals Incorporated · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  14. US 12103907

    Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

    Arcus Biosciences, Inc. · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  15. US 12097262

    mTORC1 inhibitors

    The Regents of the University of California · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  16. US 12097213

    Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation therapy

    The Board of Regents of the University of Texas System · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  17. US 12097210

    Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

    Corcept Therapeutics Incorporated · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  18. US 12083098

    Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form β inhibitors

    ACTUATE THERAPEUTICS INC. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  19. US 12083141

    Treatment of hyperglycemia with solute carrier family 39 member 5 (SLC39A5) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  20. US 12083137

    Triazole bisphosphonate geranylgeranyl diphosphate synthase inhibitors

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  21. US 12084438

    GCN2 inhibitors and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  22. US 12084447

    SHP2 phosphatase inhibitors and methods of use thereof

    Relay Therapeutics, Inc. · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  23. US 12083113

    Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients

    Northwestern University · Granted Sep 10, 2024 · Expires Sep 5, 2044

    granted
  24. US 12077506

    Indane derivatives as hypoxia inducible factor-2(α) inhibitors

    NIKANG THERAPEUTICS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted